Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vincamine is an indole alkaloid derived from the leaves of the Vinca minor (lesser periwinkle) plant. It is recognized for its cognitive-enhancing and vasodilatory effects, particularly in cerebral blood vessels. Classified as a nootropic and a vasodilator, it is used in Europe as a prescription medicine for conditions such as cerebrovascular insufficiency, age-related cognitive decline, Alzheimer's disease, and other forms of dementia. In the United States, it is sold as a dietary supplement. Its primary mechanism of action involves enhancing cerebral blood flow by inhibiting phosphodiesterase, which leads to increased cyclic adenosine monophosphate (cAMP) levels and subsequent vasodilation. Vincamine also exhibits neuroprotective properties by reducing oxidative stress and mitigating excitotoxicity, and may modulate neurotransmitter systems like dopamine and serotonin. Additionally, it has been investigated for its anticancer potential and has shown hypoglycemic and hypolipidemic activities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vincamine.